By Kashish Tandon (Reuters) -Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after ...

Glenmark Pharma's licensing deal with AbbVie will make it cash positive, improving its financial position and liquidity, according to S&P.

Glenmark, through wholly-owned subsidiary IGI Therapeutics SA, announced an exclusive licensing agreement with AbbVie for ISB ...

Glenmark Pharmaceuticals is set to become net cash positive through its licensing agreement with AbbVie Inc. This move aims ...

Pharma giants like Cipla, Glenmark, and Emcure are stepping into the booming skincare market, challenging beauty brands with ...

Choice Institutional Equities has reiterated its positive stance on Glenmark Pharma following a major licensing deal between ...

Glenmark Pharmaceuticals share price surged 10% to an all-time high of ₹2,094 following the announcement of an exclusive ...

Glenmark Pharmaceuticals Ltd is quoting at Rs 2235, up 0.4% on the day as on 12:44 IST on the NSE. The stock is up 58.13% in last one year as compared to a 1.63% gain in NIFTY and a 8.9% gain in the ...

Glenmark Pharmaceuticals shares rallied 10% on Friday to reach a record high after its biotech subsidiary signed a ...

We are just trying to regroup. One wrong move takes you back by four or five years,' Glenn Saldanha said, emphasising caution ...

Glenmark Pharmaceuticals Ltd is quoting at Rs 2214.7, up 1.54% on the day as on 12:49 IST on the NSE. The stock is up 57.28% in last one year as compared to a 1.88% jump in NIFTY and a 7.85% jump in ...

With the stock currently trading at Rs 2,225.80, Glenmark Pharma has shown a positive movement of 2.05% in today's session.